Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046267 · ClinicalTrials.gov registry record · NA
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
A NA study of HIV Infections and Diabetes Mellitus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 16
- Study locations
NCT00046267: Completed NA study of HIV Infections and Diabetes Mellitus, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00046267 is a NA study of HIV Infections and Diabetes Mellitus that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 30 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 16 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046267, a NA study of HIV Infections and Diabetes Mellitus, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and tolerability of extended-release niacin (Niaspan) in improving the level of fats in the blood of HIV-infected patients.
Conditions Studied
Interventions
- DRUG Niacin
Study Locations (16)
California
- UCLA School of Medicine - Los Angeles
- Univ of California, San Diego Antirviral Research - San Diego
- San Mateo County AIDS Program - Stanford
- Stanford Univ - Stanford
- Willow Clinic - Stanford
Indiana
- Indiana University Hospital - Indianapolis
- Methodist Hosp of Indiana - Indianapolis
- Wishard Hospital - Indianapolis
Missouri
- St. Louis Connect Care - St Louis
- Washington Univ (St. Louis) - St Louis
Ohio
- Univ of Cincinnati - Cincinnati
- Case Western Reserve Univ - Cleveland
Colorado
- Univ of Colorado Health Sciences Ctr, Denver - Denver
Florida
- Univ of Miami School of Medicine - Miami
Minnesota
- Univ of Minnesota - Minneapolis
Pennsylvania
- Univ of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | NA |
What the finished NCT00046267 record still lists
NCT00046267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Niacin is the first listed.
NCT00046267 lists 16 locations in 8 states (California, Indiana, Missouri).
Frequently Asked Questions
What is clinical trial NCT00046267 about?
NCT00046267 is a clinical study titled "Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients". The purpose of this study is to evaluate the safety, efficacy, and tolerability of extended-release niacin (Niaspan) in improving the level of fats in the blood of HIV-infected patients.
What is the current status of trial NCT00046267?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants.
What conditions does trial NCT00046267 study?
This clinical trial studies the following conditions: HIV Infections, Diabetes Mellitus, Hypercholesterolemia, Hypertriglyceridemia.
What interventions are being tested in trial NCT00046267?
The interventions under investigation include: Niacin (DRUG).
Who is sponsoring clinical trial NCT00046267?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00046267 being conducted?
This trial has 16 study locations across California, Colorado, Florida, Indiana, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00046267's enrollment target sits among peer trials
30 426th of 542 higher than 102 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer